Abstract A sequential treatment approach is the rule in CML and Ph + ALL with imatinib failure being followed by second-line tyrosine kinase inhibitors. The sequential strategy may be vulnerable to compound mutations. An alternative and fascinating hypothesis discussed in this paper is the upfront use, at least in very high-risk Ph + leukemias, of ABL kinase inhibitor combinations, either simultaneously or sequentially to target a wider range of mutations-based drug resistance. The main questions are: will TKI cocktails be able to eliminate the leukemic compartment? Which are the correct doses? Which are the long-term effects? Clinical trials have been recently initiated, and the future will give us the answer to all these questions.
Therapy with imatinib mesylate has revolutionized the management and prognosis in patients with chronic myeloid leukemia (CML). In 2009, the majority of patients diagnosed with chronic phase CML (CP-CML) can expect to have durable responses with good quality of life [1] . While a majority of patients with CP-CML have an excellent durable response to imatinib, a clear minority of them will unfortunately have signs of primary or secondary resistance to therapy. Significant efforts geared toward understanding the molecular mechanisms of imatinib resistance have yielded valuable insights into the biology trafficking, epigenetic control of cellular processes, and alterations in enzymatic structures [2] . The recent results presented at American Society of Hematology (ASH) 2009 gave rise to the question as to whether one of the new second-generation TKIs (dasatinib or nilotinib) should be offered as initial therapy instead of imatinib. Despite that both these drugs seem to be able to determine cytogenetic and molecular responses more rapidly, we do not know if such apparent short-benefit will translate into long-term benefit [3] . The tyrosine kinase inhibitors (TKIs) has become an integral part of front-line therapy also for Ph + acute lymphoblastic leukemia (ALL), with remission rates exceeding 90%, irrespective of whether imatinib is given alone or combined with chemotherapy. Although accumulating evidence suggests that TKI regimens may also improve long-term outcome in Ph + ALL, many of these patients relapse and die of leukemia [4] [5] [6] [7] .
More than 70 different Kinase domain (KD) mutations have been identified in Ph + ALL and CML, which can be assigned to four major groups based on their locations: the ATP binding loop (∼40% of the mutations), the gatekeeper residue Thr315 (25% of the mutations), the catalytic domain (25% of the mutations), or the activation loop (5% of the mutations) [8] [9] [10] . The presence of KD mutations has been studied mainly in advanced-stage CML patients or those resistant to imatinib [11] . In both situations, KD mutations are frequently present thus establishing at least a temporal association with advanced-phase disease or loss of response. Unfortunately, the prognostic implication of KD mutations for progression-free survival has not been established since there are no published studies in which resistant and non-resistant patients have been monitored for mutations systematically. Recently, a German team examined the prevalence of KD mutations of newly diagnosed and imatinib-naïve Ph + ALL patients and assessed their clinical relevance in the setting of uniform front-line therapy with imatinib [12] . A KD mutation was detected in 40% of newly diagnosed and imatinib-naïve patients; at relapse, the dominant cell clone harbored an identical mutation in 90% of patients. The conclusion was that BCR-ABL mutations are present in a substantial proportion of patients with de novo Ph + ALL. We have recently analyzed the ABL mutational status on samples collected at diagnosis in a cohort of 43 patients with untreated early CP-CML seen at our institution [13] . Mutations were identified by direct sequencing with BigDye Terminator v 1.1. cycle sequencing kit (Applied Biosystems) and analyzed with a 3130 ABI capillary electrophoresis system. Eight out 13 of (61.5%) high Sokal/Euro risk patients showed the following mutations: Y253C, S265R, E255K, F359Y, N374S, and E255V (in three cases). Three patients with Y253C, E255K, and S265R progressed during imatinib and subsequent secondgeneration TKI therapy and died of leukemia at 23, 33, and 69 months. We can reasonably hypothesize that Y253C and E255K mutations are resistant mutations since during the follow-up they maintained the same mutation found at diagnosis; the other mutation (S265R) disappeared under imatinib and was substituted by E255L which resulted to be refractory to imatinib and second-line TKI. Another patient with intermediate Sokal/Euro risk showed a D363G mutation at diagnosis, progressed under imatinib, was allografted, and he is now alive in major molecular remission. No low-risk patient carried KD mutations at diagnosis. In conclusion, KD mutations may also be present in de novo high Sokal/Euro risk CML patients and can be associated with high-level imatinib resistance and relapse.
Despite the success of imatinib in these diseases, two problems are now at the forefront of research: (a) relapse on imatinib therapy, which is generally limited to Ph + ALL and high Sokal/Euro risk CML patients and (b) persistence at molecular level of disease in many patients. A common cause of imatinib resistance seems to be point mutations in the ABL kinase domain [14] , which preclude the binding of imatinib and impede the contact between BCR-ABL and imatinib [15] ; other mutations alter the spatial conformation of the protein [14] . There are conflicting data regarding potential differences in the prognostic significance of these mutations in terms of time to progression and survival [14] [15] [16] . Increasing evidence suggests that Src family kinase may play an important role in the development of treatment resistance and progression. Second-generation BCR-ABL inhibitors, such as dasatinib [17] , nilotinib [18] , and bosutinib [19] are capable of overcoming the majority of these mutations. Unfortunately, none of these novel TKIs significantly suppresses the proliferation of leukemia cells harboring the T315I mutation [8] . Most people feel that the incidence of this type of acquired T315I clones in early disease has been overestimated. It was quite rare in the recent CML Hammersmith experience [20] . Perhaps, this mutation might play an important clinical role in the future resulting from an increased selection pressure on resistant leukemic subclones; therefore, the need for alternative therapeutic strategies is obvious. An impressive array of compounds is currently undergoing preclinical evaluation but a discussion of all of these exceeds the scope of this paper. Aurora kinases play a critical role in the regulation of mitotic processes during cell division [21, 22] . The potential therapeutic value of targeting Aurora kinases has become a focus of anticancer therapy [23, 24] . Most recently, the Aurora kinase inhibitor VX-680/MK-0457 was found to be active ex vivo against cells from patients harboring the BCR-ABL-T315I mutation [25] ; in parallel, clinical responses were achieved in patients bearing T315I-mutated BCR-ABL [26] . Unfortunately, this compound was stopped due to unacceptable toxicity. A novel kinase inhibitor, namely PHA-739358, targeting wild-type or mutant BCR-ABL, represents a promising new treatment strategy for patients with imatinib-resistant CML and resulted active against T315I [27] . More recently, new compounds have been extensively addressed at the last ASH meeting in New Orleans; in particular, they include omacetaxin [28] , the dual BCR-ABL, and Aurora kinase inhibitor AS-703569 [29] and everolimus (mTOR inhibitor) [30] . Additional studies need to be done to explore efficacy and toxicity.
A sequential treatment approach is the rule in Ph + leukemias, with imatinib failure being followed by either nilotinib or dasatinib therapy. The sequential strategy may be vulnerable to compound mutations, though such mutations may occur at exceedingly low frequency. As recently stated, an alternative fascinating and attractive approach to increasing the efficacy of imatinib in Ph + ALL but also for selected patients with high-risk Sokal/Euro CML would be to combine its use, either simultaneously or sequentially, with nilotinib or dasatinib; such trials are now in progress in USA and in Italy [3] . Clinical studies assessing the safety of combining ABL kinase inhibitors are ongoing in CML [31] . The main questions are: will cocktails of TKI be able to eliminate the leukemic compartment? Which are the correct doses? Which are the long-term effects? It is possible that, giving TKI in combination, they may turn out very toxic? Such trials are now in progress, and the future could give us the answer to these questions.
